Comparing oxygen levels during stroke treatment

Oxygenation Targets for Endovascular Therapy in Acute Ischemic Stroke Patients (Oxy-TARGET)

Not applicable Interventional Beijing Tiantan Hospital · NCT06224426

This study is testing whether giving patients with a stroke high or low levels of oxygen during treatment can help them recover better and safely.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years and up
SexAll
SponsorBeijing Tiantan Hospital Academic / other
Locations1 site (Beijing, Beijing Municipality)
Trial IDNCT06224426 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the effects of different concentrations of normobaric oxygen on early neurological improvement in patients with acute ischemic stroke undergoing endovascular therapy. Participants will be randomly assigned to receive either high-concentration oxygen (FiO2=80%) or low-concentration oxygen (FiO2=30%) during the procedure. The study will assess both the efficacy of oxygen concentration on neurological outcomes and the safety of these oxygen levels. It is a randomized controlled trial planned to enroll 200 patients at Beijing Tiantan Hospital from 2024 to 2026.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with anterior circulation occlusive stroke confirmed by imaging and a NIHSS score between 6 and 20.

Not a fit: Patients with chronic respiratory conditions or those who have had a stroke onset beyond 24 hours may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved neurological outcomes for stroke patients receiving endovascular therapy.

How similar studies have performed: While the specific approach of varying oxygen concentrations during endovascular therapy is novel, similar studies have shown promising results in optimizing oxygen delivery in acute stroke management.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion criteria

1. Age ≥18 years.
2. Anterior circulation occlusive stroke is confirmed by CT angiography (CTA), magnetic resonance angiography (MRA) or digital subtraction angiography (DSA), and occlusions of intracranial internal carotid artery (ICA) or M1 segment of the middle cerebral artery (MCA) were involved.
3. NIHSS score at admission: 6-20.
4. Randomization can be completed within 24 hours after stroke onset.

Exclusion criteria

1. Stroke onset within 6-24 hours with a CT perfusion imaging (CTP)-assessed mismatched area\<15 ml.
2. Presence of anemia, defined as hemoglobin levels o below 120 g/L in men and below 110 g/L in women.
3. Pre-stroke modified Rankin scale (mRS) score ≥2.
4. Complicated by severe agitation and seizures.
5. Evidence of intracranial hemorrhage at admission.
6. Presence of chronic obstructive pulmonary disease, asthma, or other respiratory conditions, or requirement for daily supplemental oxygen or mechanical ventilation.
7. Baseline arterial blood gas analysis indicating impaired gas exchange: PaO2 \< 60 mmHg on room air, or oxygenation index (PaO2/FiO2) \< 300 mmHg with supplemental oxygen.
8. Emergency chest CT reveals significant pulmonary parenchymal infection.
9. An oxygen mask or ventilator must be used before anesthesia to maintain a SpO2≥94%.
10. Loss of airway protective reflex or vomiting aspiration upon admission.

Where this trial is running

Beijing, Beijing Municipality

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Ischemic StrokeEndovascular therapyAcute ischemic strokeNormobaric hyperoxiaEarly neurological improvementGeneral anesthesia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.